RESUMEN
Human papillomavirus (HPV) is closely associated with cervical cancer and other anogenital cancers or diseases, and HPV vaccination is an important measure of primary prevention. Currently, there are four licensed HPV vaccines. Clinical trials and real-world studies have confirmed the efficacy and effectiveness of the routine three-dose immunization schedule. Expanding HPV vaccination coverage can accelerate the process of cervical cancer elimination, so optimizing the immunization schedule, including extending dosing intervals and decreasing vaccination doses, is one of the key considerations for future application of HPV vaccines. This review summarized the progress related to the immunogenicity and efficacy of HPV vaccination with fewer doses and non-standard three-dose schedule.